XNAS · Healthcare · Biotechnology
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | — | -20.57 | — | $28,353 | — | +0.76% | -3.57% | — |
| 2026-04-08 | Q4 2025 | — | -1.84 | — | $4,261 | — | -5.88% | -54.21% | -84.45% |
| 2025-11-14 | Q3 2025 |
| — |
| -0.04 |
| — |
| $1,941 |
| — |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | — | -0.04 | — | $0 | — | -2.28% | +30.28% | +6.54% |
Showing last 4 quarters.